SOMNOMED LTD.

SomnoMed reported revenue of AUD 114.5m (+3%) and EBITDA of AUD 10.9m (+19%) in fiscal 2026, with the EBITDA margin rising to 9.6%. Growth was supported by stronger margins, cost control and improved cash management, while a weaker second half in Europe and currency effects weighed on results. The share closed unchanged at $0.33, near its 52-week low. For 2027, management is targeting high single-digit revenue growth and expects stable EBITDA margins; drivers should include products such as Virtus and Rest Assure and the recruitment of additional dentists. » Más en de.investing.com

SomnoMed reports H1 FY26 revenue of 60.7 million AUD (+13%) and EBITDA of 7.8 million AUD (+35%) with an EBITDA margin of 13%. The FDA has granted RestAssure approval for compliance monitoring, and manufacturing capacity was expanded by more than 20%. The company confirms its full-year guidance of 119–126 million AUD revenue and 10–12 million AUD EBITDA, and plans a soft launch of RestAssure in FY27. Risks remain competition in APAC, macroeconomic pressure and regulatory implementation risks. » Más en de.investing.com

SomnoMed recorded a record first-half 2026 revenue of $60.7m (+13%) and EBITDA of $7.8m (+35%), lifting the EBITDA margin by 200 basis points to 13%. Growth was driven by Europe (+17%) and North America (+11%), while APAC declined by 4%. The company invested in expanding manufacturing (capex $3.4m) and received FDA clearance for the Rest Assure® technology; a soft launch in FY27 is being considered. SomnoMed reaffirmed its full-year guidance (revenue $119–126m, EBITDA $10–12m) despite negative free cash flow of -$0.9m. » Más en de.investing.com